

References

A

. Aitcheston and Tan EM. (1982):-

Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol.;33:167–240.

. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, Bach JF, Piette JC, (2000) :-

Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum.;43(1):76–84.

. Arbuckle MR, McClain MT, Rubertone MV et al., (2003):-

Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. ;349(16):1526-33.

. Arnet F.C, Reveille J.D and Wilson R.W, (1988):

Systemic lupus erythematosus. Current state of the genetic hypothesis. Semin. Arthritis Rheum.; 14: 24.

. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL and Balow JE (1983):

Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382–391.

. Austin, H.A. III; Muenz, L.R.; Joyce, K.M. et al. (1984):

Diffuse proliferative lupus nephritis: Identification of specific pathologic features from renal biopsy in systemic lupus erythematosus: Stepwise multiing renal outcome. Kidney Int 25:689–695.

B

. Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Muller GA, Oestmann E, Leinenbach HP, Hepper M (2001);

Rapid improvement of SLE-specific cutaneous lesions by Clq immunoadsorption. Ann Rheum Dis, 60:898-899.

. Bigler C, Lopez-Trascasa M, Potlukova E, Moll S, Danner D, Schaller M, et al., (2008):-

Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. ;51(4):624-9.

. Boackle SA, Morris MA, Holers VM and Karp DR, (1998):-

Complement opzonization is required for presentation of immune complexes by resting peripheral blood B cells. J Immunol;161:6537–43.

. Bohana-Kashtan O, Ziporen L, Donin N, Kraus S and Fishelson Z, (2004):-

Cell signals transduced by complement. Mol Immunol;41:583-97.

. Bombardier C, Gladman DD, Utoitz MB, Caron D, and Chang CH, (1992):-

The committee on prognosis studies in SLE. Deviation of the SLEDAI:A disease activity for lupus patients. Arthritis rheum 35:630-640.

. Bowness P, Davies K.A and Norsworthy P.J, (1994):-

Hereditary C1 q deficiency and SLE Q. J. Med.; 87:455-64.

. Brams P., Black A., Padlan E.A., et al., (2001) :-

A humanized anti-human CD 154 monoclonal antibody blocks CD154-CD 40 mediated human B cell activation.; 1 (2): 277-94.

. Brunner HI, Gladman DD, Ibañez D, Urowitz MD and Silverman ED, (2008):-

Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. *Arthritis Rheum.* ;58(2): 556-62.

. Bruns A, Amoura Z, Koutouzov S and Piette JC, (2000):-

The role of nucleosomes in lupus. *Curr Opin Rheumatol*;12:369-73.

. Bujan S, Ordi- Ros J, Paredes J, Mauri M, Matas L, Cortes J and Vilardell M (2003):

Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. *Ann Rheum Dis*; 62 (9):859- 865.

. Burstein D.M., Schwartz M.M and. Korbet S.M (1991) :-

Percutaneous renal biopsy with the use of real-time ultrasound.
Am. J. Nephrol. pp. 195–200.



. Cameron JS, (1999):-

Lupus nephritis. *J. Am. Soc. Nephrol.*;10:413–424.

. Carneiro E., Reis C., Pinto P., ET AL., (2006) :-

Systemic lupus erythematosus: imaging of central nervous system involvement by magnetic resonance. Acta Med Port.; 19(6):459-65. Epub May 14.

.Carroll M, (2004):-

A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol; 4: 825–30.

. Churg J, Bernstein J and Glassock R.J, (1995):-

Lupus nephritis. En: Classification and Atlas of Glomerular Disease, 2nd ed. New York, Igaku-Shoin, , p51.

. Coblyn J.S., and Weinblatt M.E. (1997):-

Rheumatic diseases and the heart. "SystemicLupus Erythematosus", In: Heart disease. " A textbook of cardiovascular medicine. Edited by: Braunwald E., 5th edition; Chap. 56: P. 1776.

. Cohen M.R., and Isenberg D.A. (1996):-

Ultraviolet irradiation in systemic lupus erythematosus: Friend or foe? Br. J. Rheumatol.;35: 1002.

. Contreras G, Pardo V, Leclercq B, et al., (2004):-

Sequential therapies for proliferative lupus nephritis. N Engl J Med. ; 350 (10): 971-80.

. Coremans IE, Spronk PE, Bootsma H et al., (1995):-

Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis; 26: 595–601.

.Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS (2007):-

Prevalence of chronic kidney disease in the United States. JAMA.;298(17):2038-47.

. Crow MK, (2008):-

Collaboration, genetic associations, and lupus erythematosus. N Engl J Med. ;358(9):956-61.

. Couser WG and Salant DJ, (1980):

Changes in antibodies J; C1q predict renal relapse in systemic lupus erythematosus. Am. J. Kidney Dis.; 26: 595-601.

D

. Dacie JV and Lewis SM. (1985):-

Practical Haematology 8th ed. Churchill Livingstone.;210-60

. Dayal N.A., Gordon C., Tucker L. and Isenberg D.A., (2002):-

The SLICC damage index: past, present and future, Lupus 11 (4), pp. 261–265.

. David W, Xamont D and Mai Kirn Lai, (2006):-

Systemic lupus erythematosus. Rheum Dis Clin North Am. ; 32(1): 150-160.

. Davies KA, Hird V, Stewart S *et al.*, (1990) :-

A study of in vivo immune complex formation and clearance in man. J Immunol;144:4613–20.

. Davis JC, Tassiulas IO, Boumpas DT. , (1996) :-

Lupus nephritis. Curr. Opin. Rheumatol.;8:415–42310.

. D'Agati VD and Appel GB. (2007) :-

Lupus Nephritis Pathology and Pathogenesis. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. 7th ed . Philadelphia,PA: Lippincott Williams & Wilkins; :1094-111.

. Diaz-Buxo J.A. and Donadio J.V, (1975) :-

Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin. Nephrol. 4, pp. 223–227

. Dooley MA and Ginzler EM (2006):-

Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am. ;32(1):91-102.

. Dooley MA., Wallace DJ, Hahn BH, et al., (2007) :-

Clinical and laboratory features of lupus nephritis. In: eds. Dubois' Lupus Erythematosus. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; :1112-30.

E

. Edworthy S.M. (2001):-

"Clinical manifestations of systemic lupus erythematosus". In: Kelley's textbook of Rheumatology. Edited by: Ruddy S., Harris E.D., Sledge C.B, 6th edition.; Saunders, Philadelphia. Chap. 74: P. 11 OS-1123.

. Edworthy S.M. (2005):-

Clinical manifestations of systemic lupus erythematosus. In: Kelley's textbook of rheumatology. Edited by: Harris E.D., Budd R.C., and Sledge C.B. 7th edition. Elsevier, Saunders. Chap. 75; P. 1201.

. Emori A., Matsushima, E., Aihora, O., Ohta K., Koime R., Miyasaka N. and Kato M. (2005):-

Cognitive dysfunction in systemic lupus erythemtaosus. Psych Clin Neuroscience., 59: 584-589.

F

. Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Shao FM, Zhao MH, (2009):-

Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant , 24:172-178.

. Frémeaux BV, Hélène NL and Schifferli JA. (2002) :-

No lupus nephritis in the absence of anti C1q autoantibodies. Nephrol Dial Transplant 17: 2041-2043.

. Furie R. (2006):-

Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am. ;32(1):149-56.

G

. Gallelli B, Moroni G, Sinico RA, Rimoldi L, Radice A, Bianchi L. (2009):-

Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci.;1173:47-51.

. Garton M.J., and Isenberg D.A. (1997):-

Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. Br. J. Rheumatol.; 36: 1067.

. Ghebrehiwet B and Peerschke EI. (2004) :-

Role of C1q and C1q receptors in the pathogenesis of systemic lupus erythematosus. Curr Dir Autoimmun;7:87–97.

. Gigante A., Amoroso D., et al., (2006):-

Systemic lupus erythematosus and renal involvement: which role of cytokines expression?. Eur Rev Med Pharmacol Sci.; 10 (5):223-8.

.Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT. (2005) :-

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. ;353(21):2219-28.

. Gladman D.D, Urowitz M.B and Goldsmith C.H. *et al.*, (1997):-

The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus, Arthritis and Rheumatism 40 (5), pp. 809–813.

. Gladman D.D., and Urowitz M.B., (1997): -

"Systemic lupus erythematosus, clinical and laboratory features".

Primer on the Rheumatic Diseases, 11th edition. Klippel J.H. (editor), Chap. 19:215-257.

. Gladman D.D. and Urowitz M.B., (1999):-

The SLICC/ACR damage index progress report and experience in the field, Lupus (8), pp. 632–637.

. Gordon K.W, Michelle P. (2005):-

Assessment of systemic lupus erythematosus. Clin Exp Rheumatol; 23 (Suppl. 39) S120-S132.

.Gourley MF, Austin HA 3rd, Scott D, et al. (1996):-

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. ;125(7):549-57

. Grande JP, (1998):-

Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus. ;7(9):604-10

.Grande JP and Balow JE, (1998):-

Renal biopsy in lupus nephritis. Lupus. ;7(9):611-7.

.Greisman SG, Redechan PB, Kimberley RP and Christian C.L, (1987):-

Differences among immune complexes; association of clq in SLE immune complexes with renal disease. *J Immunol*, 138:739-45.

.Grimaldi CM, Michael DJ, and Diamond B, (2001):-

Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. *J. Immunol.* 167: 1886-1890.

.Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, Daha MR, Berden JH. (2007):-

A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. *Annals of rheumatic diseases*, pp 693-696.

.Gunnarsson I, Ronneild J, Huang YM, Rogberg S, Nilsson B, Lundberg I and Klareskog L, (1997):-

Association between ongoing anti C1q antibody production in peripheral blood and proliferative nephritis in patients with active SLE. *British Journal of Rheumatology*; 36: 32-37.

.Gunnarsson I, Sundelin B, Heimbürger M *et al.*, (2002):-

Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. *J Rheumatol*; 29:693–9.

H

. Hahn BH, (1998):-

Antibodies to DNA. N Engl JMed;338:1359-68.

. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al., (2008) :-

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXX, KIAA1542 and other loci. Nat Genet. ;40(2):204-10.

. Harley JB, Kelly JA, Kaufman KM, (2006) :-

Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol.; 28(2): 119-30.

. Harley J.B., Sestak A.I, and Willis L.F. (1992):-

A model for disease heterogeneity in systemic lupus erythematosus. Arthritis Rheum. 32: 826

.Hertig A, Droz D, Lesavre P, et al., (2002):-

SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis; 40:1179-1184.

. Hildebrand J, Muller D, Carlos J L, Talavera F and Herbert SD, (2005):-

Systemic lupus erythematosus. *Arthritis & rheum.*; 52 (1):201-211.

.Hogarth MB, (1996):-

Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. *Clin. Exp. Immunol.*;104:241–246.

. Holers V.M. (1998):

Principles and practices of clinical immunology. Rich R., ed. 2nd edition. Mosbey, St Louis. P: 363-91.

. Horak P, Hermanova Z, Zadrazil J, Ciferska H, Ordeltova M, Kusa L, Zurek M, Tichy T (2006):-

C1q complement component and -antibodies reflect SLE activity and kidney involvement. *Clin Rheumatol* , 25:532-536.

. Horvath L, Czirjak L, Fekete B, Jakab L, Prohaszka Z, Cervenak L, Romics L, Singh M, Daha MR and Fust G, (2001):-

Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. *Immunol Lett* , 75:103-109.

. Horvath L, (2001):-

High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol.;19:667–672.

. Houssiau FA and Ginzler EM, (2008):-

Current treatment of lupus nephritis. Lupus. ;17(5):426-30.



.Ichida S, Yusawa Y, Okada H, Yoshioka K, Matsuo S, (1994):-

Localization of the complement regulatory proteins in the normal human kidney. Kidney Int;46:89–104.

.Inal JM, Hui KM, Miot S *et al.*, (2005):-

Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J Immunol;174:356–66.

.Isenberg DA and, Gordon C, (2000):-

From BILAG to BLIPS- Disease activity assessment in lupus: past, present and future. Lupus.. 9: 651-654.

.Isenberg DA, Liang MH, Fortin PR, Snaith L, (1997):-

Quantitative clinical assessment of disease activity in systemic lupus

erythematosus: progress report and research agenda. Rheumatol Int. :11(3):1.

.Isenberg DA, Rahman A, Allen E et al., (2004):-

Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2nd edition; 44 902-906.



. Jacob CO, Fronek Z. and Lewis GD. (1990):-

Heritable major histocompatibility complex class II associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA; 87: 1233.

. Jonsson H, Sturfelt G, Mårtensson U, Truedsson L, Sjöholm AG, (1995):-

Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus. Clin Exp Rheumatol;13:573–80.

K

.Kaisho T, Takeda K, Tsujimura T et al., (2001):-

L kappa B kinase alpha is essential for mature B cell development and function. J Exp Med. 193: 417-426.

.Karamelic J, Subasic D, Gavrankapetanovic F et al., (2007):-

The incidence of antinuclear antibodies (ANA) detected by indirect immunofluorescence assay (IFA) method. Med Arh; 61 (1) 9-16.

.Kawata Jk, Wener MH and Mannik M, (2002):-

The effect of high salt concentration on detection of serum immune complexes and autoantibodies to C1q in patients with systemic lupus erythematosus. J Rheumatol; 29:84–89.

.Klippel JH (1994):-

Systemic lupus erythematosus.In: Rheumatology. John H. Klippel and Paul A. Diepp (eds). 1st edition. Mosby, London, Philaelfhia. Pp: 1230.

.Kirou KA, Salmon JE and Crow MK, (2006):-

Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum Dis Clin North Am. ;32(1):103-19, ix

L

.Lahita RG, (1992):-

Early diagnosis of systemic lupus erythematosus in women. Women health ,p1-17.

.Lockshin MD and Kirkland M, (2007):-

Biology of sex distribution of systemic lupus erythematosus. Arthritis Rheum. ; 57 (4) : 608-611.

.Looney RJ, Anolik J, Sanz I, (2006):-

New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am. ; 32 (1): 201-15, xi.

M

.Magid MS, Kaplan C and Sammaritano LR, (1998):-

Placental pathology in systemic lupus erythematosus: A prospective study. Am. J. Obstet. Gynecol.; 179: 226.

. Mandell B.F., and Hoffman G.S. (2001):-

Rheumatic diseases and the cardiovascular system. In: "Heart disease". A textbook of cardiovascular medicine. 6th ed., W.B. Saunders Company.; Chap.67: P. 2199.

. Manger, Seelen, Marc A; Trouw, L A; Daha, M R , (2003):-

Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Current Opinion in Nephrology and Hypertension: November 2003 - Volume 12 - Issue 6 - pp 619-624

.Mannik M and Wener MH, (1997) :-

Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum; 40:1504–1511

. Mannik M, Merrill CE, Stamps LD, Wener MH, (2003) :-

Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol.;30:1495–1504.

. Manzi S, Navratil JS, Ruffing MJ *et al.*, (2004) :-

Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum;50:3596–603.

]

. Marisa SK, Barry LM, Robert K, PharmD. Thomas JA Lehman, Daniel Ranch.Norman T Ilowite, (2004);

Systemic Lupus Erythematosus, Current Opinion in Rheumatology.;16:577-587.

. Marks SD, Pilkington C, Woo P and Dillon MJ, (2004):-

The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 43 (9): 1186-1189.

. Marto N, Bertolaccini ML, Calabuig EJ, Hughes GRV and Khamashta MA (2005):-

Anti-Clq antibodies in nephritis: correlation between titers and renal disease activity and positive predictive value in SLE. Ann Rheum Dis;64:444-448

. McDonagh J.E, Khamashta MA,and Menon S, (1997):

A young woman with SLE: Diagnostic and therapeutic challenges. Lupus; 6: 633.

. Medzhitov R and Janeway C.,(2000) :-

Innate immunity. New Engl J Med;343:338–44.

. Meola M., Barsotti G., Cupisti A., Buoncristiani E. and Giovannetti S. (1994) :-

Free-hand ultrasound-guided renal biopsy: report of 650 consecutive cases. *Nephron* **67**, pp. 425–430.

. Merrill JT, (2002):-

Measuring disease activity in systemic lupus: progress and problems. *J. Rheumatol*; 29: 2256-2257.

. Mills J.A (1994):-

Systemic lupus erythematosus, *N. Engl. J.Med.* 330,pp.1871-1879.

. Miwa T and Song W.C , (2001):-

Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. *Int Immunopharmacol*;1:445–59.

. Moder K.G., Miller T.D., and Tazelaar H.D. (1999):-

Cardiac involvement in systemic lupus erythematosus. *Mayo. Clin. Proc.*; 74(3): 275- 284.

. Mok CC and Lau CS, (2003):

Pathogenesis of systemic lupus. *J Clin Pathol*; 56: 481-90.

. Morgan BP, Walport MJ (1991):

Complement deficiency and disease. Immunol Today; 12:301-306.

. Moura C.G, Lima I, Barbosa L, Athanazio D, Reis E, Reis M, Burlingame R.W and Santiago M.W, (2009):-

Anti-C1q Antibodies: Association With Nephritis and Disease Activity in Systemic Lupus Erythematosus. Journal of Clinical Laboratory Analysis 23 : 19–23.

. Moroni G, Trendelenburg M, Del Papa N, et al., (2001):-

Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis; 37:490–498.

N

.Nath SK, Kilpatrick J, Harley JB, (2004):-

Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol. ;16(6):794-800.

.Neumann K, Wallace DJ, Azen C, et al (1995):-

Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum; 25:47-55.

.Nived O and Sturfelt G, (2004):-

ACR classification criteria for systemic lupus erythematosus: complement components. *Lupus*;13:1–3.

.Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G and Isenberg DA, (2006):-

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. *Ann Rheum Dis.* ;65(7):942-945.

.Nolsae RL, Kelly J A, Pociot F, Moser K L , Kristiansen OP, Mandrup-Poulsen T and Barley J B, (2005):-

Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia. *Genes and Immunity* 6, 699-706.

.Nossent H, Berden J and Swaak T, (2000):-

Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis. *Lupus*; 9:504–510.

O

.Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D and Stein G, (2003):-

Anti-C1q antibodies and antiendothelial cell antibodies insystemic lupus erythematosus—Relationship with disease activity and renal involvement. Clin Rheumatol;22:271–278.

.Olivier C.M, Pascale N.R, Nolwenn C, Sabine G, Elisabeth P, Gilles H, Philippe D and Sylvie C, (2009):-

Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Research & Therapy ; 11:234-242.

P

.Parks CG, Cooper GS, Hudson LL, Dooley MA, Treachvell EL, St Clair EW, Gilkeson GS, Pandey JP.(2005):-

Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T-lymphocyte associated antigen 4 genotype.Arthritis Rheum. Apr; 52(4): 1148-59.

. Perahud I.A, Titova I.P, Hidchenko S.V etal., (2004):-

Anti-C1q antibodies in SLE patients. The Jornal of Allergy and Clinical Immunology., p 132:137.

.Pisetsky DS, Gilkeson G and Clair EW, (1997):-

Systemic lupus erythematosus. Diagnosis and treatment. Med Clin North Am. ;81(1):113-128.

.Petri M, (1995):-

Clinical features of systemic lupus erythematosus (review). Curr. Opin. Rheumatol.; 7: 395.

.Petri M and Brodsky R, (2006):-

High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus ErythematosusMichelle, JAMA.; 295:559-560.

.Prokunina L and Alarcon-Riquelme M, (2004):-

The genetic basis of systemic lupus erythematosus – knowledge of today and thoughts of tomorrow. Hum Mol Genet;13(Spec. No. 1):R143–8.

R

.Rahman A and Isenberg DA, (2008):-

Systemic lupus erythematosus. N Engl J Med. ; 358(9): 929-39.

.Rahman P, Gladman DD and Urowitz MB. (1998):-

Clinical predictors of fetal outcome in systemic lupus erythematosus.
J. Rheumatol.; 25:126.

. Rahman P, Gladman DD, Urowitz MB *et al.*, (2001):-

Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus, Lupus 10 (2), pp. 93–96.

. Reefman P, Kuiper H, Limburg PC *et al.*, (2007):-

Type I interferons are involved in the development of UVB induced inflammatory skin lesions in Systemic Lupus Erythematosus (SLE) patients. Ann Rheum Dis,. 57:411.

. Richter CM, Steiner G, Smolen JS and Isenberg DA (1998):-

Erosive arthritis in systemic lupus erythematosus: Analysis of a distinct clinical and serological subset. Br. J. Rheumatol.; 37:421.

. Rollino C., Garofalo G., Roccatello D., Sorrentino T., *et al.*, (1994) :-

Colour-coded Doppler sonography in monitoring native kidney biopsies. Nephrol. Dial. Transplant **9**, pp. 1260–1263.

. Ringold, (2006):-

Systemic Lupus Erythematosus JAMA Journal. Vol (293) No (23).

. Rönnblom L and Alm GV, (2002):-

The natural interferon- α producing cells in systemic lupus erythematosus. Hum Immunol;63:1181–93.

.Rönnblom L and Pascual V, (2008):-

The innate immune system in SLE: type I interferons and dendritic cells. Lupus. ;17(5):394-9.

.Rosen CL, Rosen A, Petri M and Schlissel M, (1996):-

Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA, 93:1624-1629.

.Rothfield NF, (1993):-

SLE: clinical aspects and treatment. Arthritis and Allied conditions. A Text book of Rheumatology 12thed.l 155-1177.

.Rus V, Maury EE and Hochberg MC, (2007):-

Epidemiology of Systemic Lupus Erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; :34-44.

S

.Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A and Hughes GR, (2005):-

Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol., 30 (5): 985-992.

.Salmon JE and Kimberly RP, (2000):-

Systemic Lupus Erythematosus" In: Manual of Rheumatology and outpatient orthopedic disorders. "Diagnosis and therapy". 4th edition. Paget S.A., Gibofsky A.', and Beery J.F. (editors): 236-251.

. Scaballer JG, (1997):-

Systemic lupus erythematosus. In: Nelson Textbook of paediatrics. Behraman R.B., Kliegman R.M. and Arvin A.M.(eds). 15th edition. W.B. Saunders Company.Philadelphia, London, Toronto, Montreal, Sydney, Tokyo.Pp:673.

.Schur PH, (1993):-

"Clinical features of systemic lupus erythematosus. ". In: Kelley's Textbook of Rheumatology, 4th edition. By: Kelley W.N., Harris E.D., Ruddy S., and Sledge C.B.(eds.); W.B. Saunders Company, Philadelphia, London, Toronto. Chap. 61.: P. 1030-1039.

.Schur PH and Sandsson J, (1986):-

Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med;278:533–8.

.Seelen MA, Trouw LA and Daha MR, (2003):-

Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr. Opin. Nephrol. Hypertens.;12:619–624.

.Shoenfeld Y, Szyper-Kravitz M, Witte T, et al., (2007):-

Autoantibodies against protective molecules—C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: Prevalence in systemic lupus erythematosus. *Ann N Y Acad Sci*;1108:227–239.

.Siegert C, Daha M, Westedt ML, van der Voort E and Breedveld F, (1991):-

IgG autoantibodies against Clq are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. *J Rheumatol* 18:230.

.Siegert CE, Daha MR, Lobatto S, van der Voort EA and Breedveld FC, (1992):-

IgG autoantibodies to C1q do not detectably influence complement activation *in vivo* and *in vitro* in systemic lupus erythematosus. *Immunol Res*; 11:91–97.]

.Siegert CE, Daha MR, Swaak AJ, van der Voort EA and Breedveld FC, (1993):-

The relationship between serum titers of autoantibodies to Clq and age in the general population and in patients with systemic lupus erythematosus. *Clin Immunol Immunopathol* 67: 204-9.

.Siegert CE, Daha MR, Tseng CM *et al.*, (1998):-

Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. *Ann Rheum Dis*; 52:851–856.

.Siegert CE and Daha MR, (1998):-

C1q as antigen in humoral autoimmune responses. *Immunobiology*; 199:295-302.

.Sigurdson S, Nordmark G, Goring HH *et al.*, (2005):-

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet*;76:528–37.

.Sim RB and Laich A, (2000):-

Serine proteases of the complement system. *Biochem Soc Trans*;28:545–50.

.Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C and Arrigo G, (2006):-

Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. *Ann N Y Acad Sci.* ;1050:193-200.

.Somers EC, Marder W, Christman GM, Ogdenovski V and McCune

WJ, (2005):-

Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum.* ;52(9):2761-7.

.Sontheimer RD, (1996):-

Photo-immunology of lupus erythematosus and dermatomyositis: A speculative review. *Photochem. Photobiol.*; 63: 583.

.Steineberg AD, (1992):-

"concepts of pathogenesis of SLE". *Clin. Immunol. Immunopathol.*; 63(1): 19-25.

.Stoll T, Sutcliffe N, Mach J. *et al.*, (2004):-

Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study, *Rheumatology (Oxford)* 43 (2004) (8), pp. 1039–1044.

.Sturfelt G, Mårtensson U, Truedsson L and Sjöholm AG, (1995):-

Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus. *Clin Exp Rheumatol*;13:573–80.

.Talar-Williams C, Hijazi Y and Walther M, (2000):-

Cyclophosphamide-induced bladder toxicity in patients with Wegener's granulomatosis. *Ann. Intern. Med.*, 124: 477-484.

.Tan EM, Cohen AS, Fries JF, Masi AT et al., (1982):-

The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.*, 25:1271-1277.

.Taylor PR, Carugati A, Fadok VA et al., (2000):-

A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. *J Exp Med*;192:359–66.

.Teixeira JE, Costa RS, Lachmann PJ, Wurzner R and Barbosa JE, (1996):-

CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. *Clin Exp Immunol* ;105:497–503.

.Trendelenburg M, Marfurt J, Gerber I, Tyndall A and Schifferli JA, (1999):-

Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. *Arthritis Rheum*; 42:187–188.

.Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al., (2006):-

High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. *Nephrol Dial Transplant*;21:3115–3121.

.Tsacheva I, Radanova M, Todorova N, Argirova T and Kishore U, (2007):-

Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol;44:2147–2151.

.Tsao BP, (2004):-

Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol. ;16(5):513-21.

U

.Uwatoko S, (1987):-

C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol.;69:98–106.

V

.Vogt A, Rohrboch R, Shimizu F, Takamiya H and Batsford SR

(1982):-

Interaction of cationized antigen with rat glomerular basement membrane: in situ immune complex formation. Kidney Int. 22: 27-35.



.Walport MJ, (2001):-

Complement Second of two parts. N Engl J Med , 344:1140-1144.

.Walz Le Blanc BA, Dagenais P and Urowitz MB, (1994):-

Methotrexate in systemic lupus erythematosus. J. Rheumatol.;21: 836.

.Wang B, Gladman DD and Urowitz MB. (1998):-

Fatigue in lupus is not correlated with disease activity.. J. Rheumatol.;25: 892.

.Wallace DJ and Metzger AL. (1997):-

Systemic Lupus Erythematosus: Clinical aspects and treatment. In: Arthritis and allied conditions: A ' textbook of rheumatology. Edited

by: William J. Koopman, and Daniel J. McCarty. 13th edition. Chap. 69; P. 1319.

.Walport MJ and Lachmann PJ, (1988):-

Erythrocyte complement receptor type 1, immune complexes, and the

.Walport MJ, Davies KA and Botto M, (1998):-

Clq and systemic lupus erythematosus. Immunobiology , 265-85.

rheumatic diseases. Arthritis Rheum;31:153–158.

.Walport MJ, (2001):-

Complement. First of two parts. New Engl J Med;344:1058–66.

Walport MJ,(2002):-

Complement and systemic lupus erythematosus.Arthritis Res 4(suppl3):279-293.

.Wener MH, Uwatoko S and Marnik M, (1989):-

Antibodies to the collagen-like region of clq in patients with rheumatic diseases.Arthritis Rheum.32:544-51.

.Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE and

Appel GB, (2004):-

The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. ;15(2):241-50.

.Werth VP, Duti JP, and Southerner RD, (1997):

Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus (review). Curr. Opin. Rheumatol.; 9: 400.

.Whittier WL and Korbet SM (2004):-

Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol.;15(1):142-7.

.Winkelestein JA and Sullivan KE, (1995):-

Complement deficiencies. In: Clinical immunology principles and practice. Rich R.R. (ed). 2nd edition. Mosby, St Louis. Pp 662-76.

.Winslow TM, Ossipov MO, Fazio GP and Simonson JS (1995):-

Five- year follow- up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am. Heart J.; 129: 510- 515.

. Wiseman D.A., Hawkins R., Numerow L.M. and Taub K.J. (1990) :-

Percutaneous renal biopsy utilizing real time, ultrasonic

guidance and a semiautomated biopsy device. *Kidney Int.* **38**, pp. 347–349.

.Wisnieski JJ and Jones SM, (1992):-

IgG autoantibody to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and six other musculoskeletal or rheumatic diseases. *J Rheumatol*; 19:884–888.

.Wong M and Tsao BP, (2006):-

Current topics in human SLE genetics. *Springer Semin Immunopathol.* ;28(2):97-107.



.Yamada M, Oritani K, Kaisho T *et al.*, (2004):-

Complement C1q regulates LPD-induced cytokine production in bone marrow derived dendritic cells. *Eur J Immunol*;34:221–30.

. Yee, C.S, Isenberg D.A, Prabu A., et al., (2007) :-

BILAG-2004 Index captures SLE disease activity better than SLEDAI-2000. *Annals Rheum Dis.* 22:28.

.Yung S and Chan TM, (2008):-

Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms. Autoimmun Rev. ;7(4):317-21